Table 3 Univariate and multivariate analyses of survival after SCS in patients with endometrial carcinoma

Age at recurrence (years)

0.701

0.165

 < 60

1

1

 ≥ 60

1.171 (0.522–2.630)

1.847 (0.777–4.392)

ECOG performance status before SCS

0.719

0.385

 0

1

1

 1–2

0.802 (0.241–2.672)

1.620 (0.545–4.818)

FIGO stage at initial diagnosis

0.629

0.396

 I/II

1

1

 III/IV

1.238 (0.520–2.948)

1.482 (0.597–3.675)

Histology

 Endometrioid

1

1

 Serous

1.412 (0.329–6.065)

0.642

1.722 (0.395–7.510)

0.469

 Clear cell

5.879 (0.726–47.617)

0.097

7.544 (0.897–63.485)

0.063

 Carcinosarcoma

1.366 (0.405–4.609)

0.615

0.973 (0.224–4.235)

0.971

Tumor grade

0.081

0.014

0.002

 G1/G1-G2/G2

1

1

1

 G2-G3/G3

2.231 (0.907–5.488)

4.166 (1.339–12.962)

11.236 (2.446–51.623)

Previous radiotherapy

0.896

0.750

 No

1

1

 Yes

0.931 (0.321–2.705)

1.194 (0.401–3.552)

Clinical symptoms at recurrence

0.799

0.832

 No

1

1

 Symptomatic

0.904 (0.415–1.969)

0.911 (0.383–2.163)

Size of largest tumor (cm)

0.058

0.007

0.033

 ≤ 6

1

1

1

 > 6

2.591 (0.968–6.94)

4.115 (1.472–11.499)

4.408 (1.128–17.229)

Number of recurrent tumors

0.017

0.133

0.024

0.004

 One

1

1

1

1

 Several

2.684 (1.189–6.057)

2.315 (0.744–6.927)

2.859 (1.145–7.138)

9.672 (2.032–46.025)

DFI before SCS (months)

0.026

0.451

0.085

 < 12

1

1

1

 ≥ 12

0.409 (0.186–0.898)

0.710 (0.291–1.732)

0.466 (0.196–1.110)

Retroperitoneal lymph node metastasis

0.425

0.259

 No

1

1

 Yes

0.671 (0.253–1.786)

0.495 (0.146–1.681)

Distant metastasis

0.018

0.399

0.039

0.183

 No

1

1

1

1

 Yes

2.763 (1.188–6.426)

1.672 (0.506–5.524)

2.616 (1.052–6.508)

3.185 (0.579–17.537)

Lung metastasis alone

0.396

0.493

 No

1

1

 Yes

2.402 (0.318–18.132)

2.023 (0.270-15.174)

Peritoneal dissemination

0.034

0.564

0.005

0.381

 No

1

1

1

1

 Yes

2.488 (1.071–5.781)

0.610 (0.114–3.271)

3.696 (1.498–9.120)

0.393 (0.049–3.169)

Vaginal wall metastasis alone

0.133

0.193

 No

1

1

 Yes

0.036 (0.000-2.765)

0.037 (0.000-5.315)

Ascites

0.001

0.302

0.000

0.522

 None

1

1

1

1

 Yes

4.962 (1.884–13.069)

2.55 (0.431–15.094)

6.119 (2.229–16.794)

1.723 (0.325–9.128)

 Residual disease

0.017

0.263

0.022

0.401

 None

1

1

1

1

 > 0

2.956 (1.216–7.187)

1.857 (0.628–5.495)

2.918 (1.170–7.280)

1.605 (0.532–4.849)

Neoadjuvant chemotherapy before SCS

0.788

0.541

 No

1

1

 Yes

1.219 (0.288–5.168)

1.576 (0.366–6.794)

Adjuvant therapy after SCS

 None

1

1

1

1

 Chemotherapy only

0.656 (0.238–1.810)

0.416

0.489 (0.148–1.613)

0.240

0.560 (0.198–1.583)

0.274

0.083 (0.017–0.416)

0.002

 Radiotherapy only

0.054 (0.006–0.469)

0.008

0.105 (0.010–1.150)

0.065

0.069 (0.008–0.597)

0.015

0.053 (0.003–0.934)

0.045

 Hormonal therapy

0.163 (0.043–0.623)

0.008

0.187 (0.029–1.196)

0.077

0.103 (0.020–0.538)

0.007

0.063 (0.006–0.648)

0.020